Poly (ADP-ribose) polymerase inhibition attenuates atherosclerotic plaque development in ApoE -/- mice with hyperhomocysteinemia

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 5, 2009, Pages 641-653

  Xie, Jiang Jiao ^a   Yu, Xian ^a   Liao, Yu Hua ^a   Chen, Jian ^a   Yao, Rui ^a   Chen, Yong ^a   Liao, Meng Yang ^a   Ding, Ying Jun ^a   Tang, Ting Ting ^a   Cheng, Xiang ^a  

^a Union Hospital   (China)

Author keywords

Atherosclerosis; Hyperhomocysteinemia; Oxidative stress; Proinflammatory

Indexed keywords

3 AMINOBENZAMIDE; APOLIPOPROTEIN E; HOMOCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; GENE TRANSLOCATION; HYPERHOMOCYSTEINEMIA; LIPID ANALYSIS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 73249118267     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.1586     Document Type: Article

References (52)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA, 1995; 274: 1049-1057
2. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA: Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation, 1997; 95: 1119-1121
3. Lang D, Kredan MB, Moat SJ, Hussain SA, Powell CA, Bellamy MF, Powers HJ, Lewis MJ: Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: Role for superoxide anions. Arterioscler Thromb Vasc Biol, 2000; 20: 422-427
4. McDowell IF, Lang D: Homocysteine and endothelial dysfunction: A link with cardiovascular disease. J Nutr, 2000; 130 (2S suppl): 369S-372S
5. Harrison DG, Cai H, Landmesser U, Griendling KK: Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst, 2003; 4: 51-61
6. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev, 2007; 87: 315-424
7. Rubbo H, O'Donnell V: Nitric oxide, peroxynitrite and lipoxygenase in atherogenesis: Mechanistic insights. Toxicology, 2005; 208: 305-317
8. Garcia Soriano F, Virág L, Jagtap P, Szabó E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabó C: Diabetic endothelial dysfunction: The role of poly (ADP -ribose) polymerase activation. Nat Med, 2001; 7: 108-113
9. Pieper AA, Walles T, Wei G, Clements EE, Verma A, Snyder SH, Zweier JL: Myocardial postischemic injury is reduced by poly (ADP -ribose) polymerase-1 gene disruption. Mol Med, 2006; 6: 271-282
10. Sharp C, Warren A, Oshima T, Williams L, Li JH, Alecander JS: Poly ADP -ribose polymerase inhibitors prevent the upregulation of ICAM-1 and E-selectin in response to Th1 cytokine stimulation. Inflammation, 2001; 25: 157-163
11. Hassa PO, Hottiger MO: The functional role of poly (ADP -ribose) polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci, 2002; 59: 1534-1553
12. Carrillo A, Monreal Y, Ramírez P, Marin L, Parrilla P, Oliver FJ, Yélamous J: Transcription regulation of TNF-alpha-early response genes by poly (ADP -ribose) polymerase-1 in murine heart endothelial cells. Nucleic Acids Res, 2004; 32: 757-766
13. Chiarugi A, Moskowitz MA: Poly (ADP -ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem, 2003; 85: 306-317
14. Le Page C, Sanceau J, Drapier JC, Wietzerbin J: Inhibition of ADP -ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF kappa B activation. Biochem Biophys Res Commum, 1998; 243: 451-457
15. Oliver FJ, Ménissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, de la Rubia G, Stoclet JC, de Murcia G: Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP -ribose) polymerase-1deficent mice. EMBO J, 1999; 18: 4446-4454
16. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM: Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation, 2002; 106: 927-932
17. Oumouna-Benachour K, Hans CP, Suzuki Y, Naura A, Datta R, Belmadani S, Fallon K, Woods C, Boulares AH: Poly (ADP-ribose) polymerase inhibition reduces athero-sclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death. Circulation, 2007; 115: 2442-2450
18. Zhou J, Werstuck GH, Lhoták S, Shi YY, Tedesco V, Trigatti B, Dickhout J, Majors AK, DiBello PM, Jacobsen DW, Austin RC: Hyperhomocysteinemia induced by methionine supplementation dose not independently cause atherosclerosis in C57BL/6J mice. FASEB J, 2008; 22: 2569-2578
19. Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K, Ishibashi M, Hiasa K, Nishida K, Takeshita A: Antimonocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation, 2002;106: 2700-2706
20. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA: Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis, 1987; 68: 231-240
21. Cheng X, Chen Y, Xie JJ, Yao R, Yu X, Liao MY, Ding YJ, Tang TT, Liao YH, Cheng Y: Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE (-/-) mice through modulation of Th1/Th2 balance. J Mol Cell Cardiol, 2008; 45: 168-175
22. Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, Imaizumi K, Akiyama C, Nishida KI, Takeshita A: New Anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation, 2001; 103: 2096-2101
23. Schubert SY, Neeman I, Resnick N: A novel mechanism for the inhibition of NF-kappaB activation in vascular endothelial cells by natural antioxidants. FASEB J, 2002; 16: 1931-1933
24. Siow YL, Au-Yeung KK, Woo CW, O K: Homocysteine stimulates phosphorylation of NAPDH oxidase p47phox and p67phox subunits in monocytes via protein kinase Cbeta activation. Biochem J, 2006; 398: 73-82
25. Tasatargil A, Dalaklioglu S, Sadan G: Poly (ADP-ribose) polymerase inhibition prevents homocysteine-induced endothelial dysfunction in the isolated rat aorta. Pharmacology, 2004; 72: 99-105
26. Joshi SG, Francis CW, Silverman DJ, Sahni SK: Nuclear factor kappa B protects against host cell apoptosis during Rickettsia rickettsii infection by inhibiting activation of apical and effector caspases and maintaining mitochondrial integrity. Infect Immun, 2003; 71: 4127-4136
27. Zhou J, Møller J, Danielsen CC, Bentzon J, Ravn HB, Austin RC, Falk E: Dietary supplementation with menthionine and homocysteine promotes early athrosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler Thromb Vasc Biol, 2001; 21: 1470-1476
28. Zhou J, Møller J, Ritskes-Hoitinga M, Larsen ML, Austin RC, Falk E: Effect of vitamin supplementation and hyperhomocysteinemia on atherosclerosis in apoE-deficient mice. Atheroscletosis, 2003; 168: 255-262
29. Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, Yang X, Berger PB, Durante W, Pownall HJ, Schafer AI: Hyperhomocysteinemia accelerates atherosclerosis in cystathiorine beta-synthase and apolipoprotein E double knock-out mice with and without dietary pertyrbation. Blood, 2003; 101: 3901-3907
30. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest, 2001; 107: 675-683
31. Werns SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, Pitt B: Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation, 1989; 79: 287-291
32. Starkebaum G, Harlan JM: Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest, 1986; 77: 1370-1376
33. Szabó C, Dawson VL: Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci, 1998; 19: 287-298
34. Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, Verma A, Wang ZQ, Snyder SH: Poly (ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci USA, 1999; 96: 3059-3064
35. Pacher P, Mabley JG, Soriano FG, Liaudet L, Komjáti K, Szabó C: Endothelial dysfunction in aging animals: The role of Poly (ADP-ribose) polymerase activation. Br J Pharmacol, 2002; 135: 1347-1350
36. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabó C: Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of Poly (ADP-ribose) polymerase. Circ Res, 2001; 89: 684-691
37. Zingarelli B, Cuzzocrea S, Zsengellér Z, Salzman AL, Szabó C: Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of Poly (ADP-ribose) synthetase. Cardiovasc Res, 1997; 36: 205-215
38. Yu X, Cheng X, Xie JJ, Liao MY, Yao R, Chen Y, Ding YJ, Tang TT, Liao YH: Poly (ADP-ribose) Polymerase Inhibition Improves Endothelial Dysfunction Induced by Hyperhomocysteinemia in Rats. Cardiovasc Drug Ther, 2009; 23: 121-127
39. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL, O K: Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res, 2004; 94: 28-36
40. Shishodia S, Aggarwal BB: Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem, 2004; 279: 47148-47158
41. D'Amours D, Desnoyers S, D'Silva I, Poirier GG: Poly (ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J, 1999; 342: 249-268
42. Chiarugi A: Poly (ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci, 2002; 23: 122-129
43. Hassa PO, Covic M, Hasan S, Imbof R, Hottiger MO: The enzymatic and DNA binding activity of PARP-1 are not required for NF-κB coactivator function. J Biol Chem, 2001; 276: 45588-45597
44. Zingarelli B, Hake PW, O'Connor M, Denenberg A, Kong S, Aronow BJ: Absence of Poly (ADP-ribose) poly-merase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury. Mol Med, 2003; 9: 143-153
45. Huang RF, Huang SM, Lin BS, Wei JS, Liu TZ: Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells. Life Sci, 2001; 68: 2799-2811
46. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earushaw WC: Cleavage of Poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature, 1994; 371: 346-347
47. Isner JM, Kearney M, Bortman S, Passeri J: Apoptosis in human atherosclerosis and restenosis. Circulation, 1995; 91: 2703-2711
48. Kockx MM, De Meyer GR, Muhring J, Bult H, Bultinck J, Herman AG: Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. Atherosclerosis, 1996; 120: 115-124
49. Hegyi L, Skepper JN, Cary NR, Mitchinson MJ: Foam cell apoptosis and the development of the lipid core of human atherosclerosis. J Pathol, 1996; 180: 423-429
50. Litttlewood TD, Bennett MR: Apoptotic cell death in atherosclerosis. Curr Opin Lipidol, 2003; 14: 469-475
51. Schraufstatter IU, Hyslop PA, Hinshaw DB, Spragg RG, Sklar LA, Cochrane CG: Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly (ADP-ribose) polymerase. Proc Natl Acad Sci USA, 1986; 83: 4908-4912
52. Szabó C, Zingarelli B, O'Connor M, Salzman AL: DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA, 1996; 93: 1753-1758